Raymond James Financial
BDTX icon

Raymond James Financial’s Black Diamond Therapeutics BDTX Stock Holding History

Raymond James Financial’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
62,235
+48,120
+341% +$118K ﹤0.01% 5154
2026
Q1 		$30.1K Buy
14,115
+647
+5% +$1.54K ﹤0.01% 5172
2025
Q4 		$32.7K Sell
13,468
-3,747
-22% -$13.3K ﹤0.01% 5045
2025
Q3 		$65.2K Sell
17,215
-19,673
-53% -$57.5K ﹤0.01% 4799
2025
Q2 		$91.5K Buy
36,888
+3,464
+10% +$6.68K ﹤0.01% 4919
2025
Q1 		$51.8K Buy
33,424
+8,432
+34% +$17.7K ﹤0.01% 4637
2024
Q4 		$53.5K Buy
+24,992
New +$71.6K ﹤0.01% 4601

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Raymond James Financial's BDTX Position: Q2 2026 in Review

Raymond James Financial increased its Black Diamond Therapeutics (BDTX) stake by 341% in Q2 2026, buying an estimated $118K and bringing the position to 62,235 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #5154.

Raymond James Financial first reported a position in BDTX in Q4 2024 and has held it in 7 quarters since. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Raymond James Financial held 62,235 shares of Black Diamond Therapeutics worth $115K as of Q2 2026.
  • Raymond James Financial bought 48,120 Black Diamond Therapeutics shares in Q2 2026, an estimated $118K.
  • Black Diamond Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5154 holding.
  • Raymond James Financial first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.